San Diego-based cancer treatment startup Erasca raised $200 million in a new round of funding, the company announced Monday.
Subscribe to the ÂÜÀòÊÓÆµ Daily
The Series B round was led by and , and included participation from new investors , and , according to a statement from the company.
Erasca, which draws its name from “erase cancer,� will use the funding to “to support the clinical development of multiple promising oncology programs and further advance the company’s in-house drug discovery pipeline,� the company said. It isn’t clear which types of cancer the company is developing treatments for.
“Unfortunately, millions of people still suffer from cancer daily,� CEO Dr. Jonathan Lim said in the statement. “At Erasca, we are doing everything we can to help these patients live longer and healthier lives by taking an aggressive long-term approach to tackling this disease with leading-edge science and world-class talent. We are immensely grateful to have new and existing shareholders who embrace our mission to erase cancer.�
The Series B round is large; $200 million is a lot of capital for such a young company. But it’s important to note that drug development isn’t a cheap endeavor, so companies taking on such a task need a lot of capital for research.
Erasca now has more than $260 million in funding, and its other backers include and , according to ÂÜÀòÊÓÆµ.
Illustration Credit:
Stay up to date with recent funding rounds, acquisitions, and more with the ÂÜÀòÊÓÆµ Daily.



67.1K Followers